Medipost Presents Plaque of Recognition to Hyukjae Yang, Chief Medical Director of Medrex Hospital, for Achieving 1,500 CARTISTEM Procedures

- Ongoing Collaboration Since 2017: Medrex Hospital Invited to Headquarters to Share Clinical Expertise
- Introduction of Personalized Treatment Strategies and Long-Term Outcomes for CARTISTEM, a Specialized Cartilage Regeneration Therapy

MEDIPOST (CEO Wonil Oh) announced on September 22 that, on September 17, the company presented a plaque of appreciation to Hyukjae Yang, Chief Medical Director of Medrex Hospital in Gangnam-gu, Seoul, to commemorate achieving 1,500 CARTISTEM® procedures.

The event was organized by inviting Medrex Hospital to MEDIPOST's headquarters to share clinical application experiences and expertise related to CARTISTEM, a treatment for knee cartilage defects.

Since its opening in 2017, Medrex Hospital has become a leading clinical partner institution, having performed over 1,500 CARTISTEM procedures. Since the same year, MEDIPOST has designated Medrex Hospital as a stem cell research partner hospital and appointed Chief Medical Director Hyukjae Yang as an advisory board member for CARTISTEM, thereby continuing collaborative efforts.

On this day, Chief Medical Director Hyukjae Yang toured MEDIPOST's research and manufacturing facilities and discussed the future direction of CARTISTEM treatment and clinical application strategies with company representatives. In the subsequent lecture, he introduced the characteristics of CARTISTEM, an umbilical cord blood-derived allogeneic mesenchymal stem cell therapy, alongside tailored treatment strategies according to the patient's degree of cartilage damage and long-term outcomes. He also shared concrete clinical insights based on actual patient case studies.

Through this event, MEDIPOST and Medrex Hospital reaffirmed their cooperative relationship focused on sharing research, development, and real-world clinical experience related to the therapeutic agent.

Previously, in February 2024, MEDIPOST had also presented a plaque of appreciation to mark the achievement of 1,000 CARTISTEM procedures. This recent visit was organized to celebrate the milestone of surpassing 1,500 procedures since then.

A MEDIPOST representative explained that the company continuously arranges opportunities to share clinical expertise, stating, "Going forward, we will continue to enhance patient treatment outcomes by sharing clinical know-how and encouraging academic exchange, while further strengthening our collaboration in stem cell research and educational fields."

This content was produced with the assistance of AI translation services.